OTCMKTS:LXRP Lexaria Bioscience (LXRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lexaria Bioscience Stock (OTCMKTS:LXRP) 30 days 90 days 365 days Advanced Chart Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.15 million shsAverage Volume608,350 shsMarket Capitalization$20.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.Read More… Receive LXRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRP Stock News HeadlinesLEXX: GLP-1-H25-5 Study CompleteJune 16, 2025 | msn.comLexaria Bioscience to Engage with Industry Leaders at BIO International ConventionJune 5, 2025 | tipranks.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)Lexaria Bioscience Stock Price, Quotes and Forecasts | NASDAQ:LEXXW | BenzingaMay 21, 2025 | benzinga.comLexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 13, 2025 | finanznachrichten.deLexaria Advances Collaboration with Pharma Partner on Drug Delivery TechnologyMay 12, 2025 | tipranks.comLexaria Bioscience Corp.: Lexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | finanznachrichten.deLexaria Bioscience Secures $2 Million in Direct Stock OfferingApril 28, 2025 | tipranks.comSee More Headlines LXRP Stock Analysis - Frequently Asked Questions How do I buy shares of Lexaria Bioscience? Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include Canopy Growth (CGC), Organigram Global (OGI), Walt Disney (DIS), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Tilray Brands (TLRY) and NVIDIA (NVDA). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Metal Mining Sub-IndustryN/A Current SymbolOTCMKTS:LXRP CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.09 million Net Margins-1,046.77% Pretax MarginN/A Return on Equity-157.62% Return on Assets-148.09% Debt Debt-to-Equity Ratio0.01 Current Ratio8.52 Quick Ratio8.01 Sales & Book Value Annual Sales$380 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares89,587,000Free FloatN/AMarket Cap$20.15 million OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:LXRP) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.